Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Finally — A Revitalized Patent Act

Related Content

The USPTO’s Increasing Focus on FDA Submissions and the Duty of Disclosure

Chief Judge of Western District of Texas Changes Waco Patent Case Assignment System

Fintiv 2.0: USPTO Director Issues Guidance Softening Risk of Discretionary Denial

Federal Circuit Clarifies Standard for Fair and Reasonable Exercise of Jurisdiction Based on Demand Letters

Aren’t You Glad 2020 Is Over? A Look Back (and Ahead)

Federal Circuit Narrows Venue for Patent Infringement Suits Under the Hatch-Waxman Act

Strategic Considerations for Seeking Patent Term Extension (PTE) and its Scope for Drug Products

Webinar Recording:
Law and Pop Culture

Utah Bar Association – Intellectual Property Law Summit

FCBA Program on 2023 Patent Law Year in Review

Litigation Financing Demystified: Insights from Funders and Counsel

Contracting Away Your IP Rights: Pitfalls to Avoid With Third Party Partners During Drug Development

Cell and Gene Therapies and Section 112: An Overview of the State of §112 Law and Considerations for Developers of Cell and Gene Therapies

CenterForce's Business Development Summit: Diverse Partners & Associates

November 2023 Meeting of the Giles S. Rich Inn of Court

Biosimilars Patent Challenges at the PTAB: Update and Lessons Learned

Patent Litigation

Patent Prosecution & Counseling